Superior virological response to boosted protease inhibitor-based highly active antiretroviral therapy in an observational treatment programme

HIV Medicine

Volumn 8, Issue 2, 2007, Pages 80-85

  Wood, E ^a,b   Hogg, R S ^a,b   Yip, B ^a   Moore, D ^a   Harrigan, P R ^a,b   Montaner, J S G ^a,b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Protease inhibitor; Rebound; Suppression; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INDINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CANADA; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG USE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME; VIRUS INHIBITION; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRITISH COLUMBIA; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; RNA, VIRAL; SEX DISTRIBUTION; TREATMENT OUTCOME;

EID: 33847791634     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2007.00430.x     Document Type: Article

References (21)

1. Hammer SM, Squires KE, Hughes MD et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337: 725-733.
2. Walmsley S, Bernstein B, King M et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346: 2039-2046.
3. King MS, Bernstein BM, Walmsley SL et al. Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients. J Infect Dis 2004; 190: 280-284.
4. Yeni PG, Hammer SM, Hirsch MS et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. J Am Med Assoc 2004; 292: 251-265.
5. Phillips AN, Grabar S, Tassie JM, Costagliola D, Lundgren JD, Egger M. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: Comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups. AIDS 1999; 13: 2075-2082.
6. Egger M, May M, Chene G et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet 2002; 360: 119-129.
7. Smith CJ, Phillips AN, Hill T et al. The rate of viral rebound after attainment of an HIV load <50 copies/mL according to specific antiretroviral drugs in use: Results from a multicenter cohort study. J Infect Dis 2005; 192: 1387-1397.
8. Hogg RS, Yip B, Chan KJ et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. J Am Med Assoc 2001; 286: 2568-2577.
9. Wood E, Hogg RS, Heath KV et al. Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies. AIDS 2003; 17: 2629-2634.
10. Heath KV, Hogg RS, Chan K et al. Lipodystrophy-associated morphological, cholesterol, and triglyceride abnormalities in a population-based HIV/ AIDS treatment program. AIDS 2001; 15: 231-239.
11. Strathdee SA, Palepu A, Cornelisse PG et al. Barriers to use of free antiretroviral therapy in injection drug users. J Am Med Assoc 1998; 280: 547-549.
12. Hogg RS, Heath KV, Bangsberg D et al. Intermittent use of triple combination therapy is predictive of mortality at baseline and after one year of follow-up. AIDS 2002; 16: 1051-1058.
13. Wood E, Montaner JS, Yip B et al. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. Can Med Assoc J 2003; 169: 656-661.
14. + cell count is 0.200-0.350 × 10(9)cells/L. Ann Intern Med 2003; 139: 810-816.
15. Wood E, Hogg RS, Yip B, Harrigan PR, Montaner JS. Why are baseline HIV RNA levels 100,000copies/mL or greater associated with mortality after the initiation of antiretroviral therapy. J Acquir Immune Defic Syndr 2005; 38: 289-295.
16. Skowron G, Street JC, Obee EM. Baseline CD4(+) cell count, not viral load, correlates with virologic suppression induced by potent antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 28: 313-319.
17. + cell strata. Ann Intern Med 2003; 138: 620-626.
18. Wood E, Hogg RS, Bonner S et al. Staging for antiretroviral therapy among HIV-infected drug users. J Am Med Assoc 2004; 292: 1175-1177.
19. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: Methods, validity, and applications. J Clin Epidemiol 1997; 50: 105-116.
20. Grossberg R, Zhang Y, Gross R. A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. J Clin Epidemiol 2004; 57: 1107-1110.
21. Gross R, Zhang Y, Grossberg R. Medication refill logistics and refill adherence in HIV. Pharmacoepidemiol Drug Safety 2005; 14: 789-793.